Abbott’s Amulet 360 achieves complete LAA closure in 96.3% of evaluated patients at one year
- Abbott announced one-year VERITAS results showing high left atrial appendage closure rates with its Amulet 360 device, with low stroke incidence.
- Results were presented Nov. 1, 2026, at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions.
- The device targets patients with non-valvular atrial fibrillation who need an alternative to long-term blood thinners.
- Amulet 360 remains investigational in the U.S.; it received CE Mark approval in August 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG86119) on November 02, 2026, and is solely responsible for the information contained therein.